# Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

> **NCT05332561** · PHASE2 · RECRUITING · sponsor: **German Cancer Research Center** · enrollment: 240 (estimated)

## Conditions studied

- Early-stage Breast Cancer

## Interventions

- **DRUG:** Atezolizumab 1200 mg in 20 ML Injection
- **DRUG:** Inavolisib
- **DRUG:** Ipatasertib
- **DRUG:** Olaparib
- **DRUG:** Sacituzumab govitecan
- **DRUG:** Trastuzumab/pertuzumab

## Key facts

- **NCT ID:** NCT05332561
- **Lead sponsor:** German Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-29
- **Primary completion:** 2030-03
- **Final completion:** 2030-12
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332561, "Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05332561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*